What is Profusa?
Profusa, Inc. is a pioneering entity dedicated to the creation of biosensors that seamlessly integrate with human tissue, enabling the real-time monitoring of vital body chemistries. Their flagship innovation, the Lumee Oxygen Platform, has achieved a CE Mark for distribution within the European Union, signaling a critical step towards commercial viability. This platform is engineered to provide continuous, in-situ measurement of tissue oxygen levels, a capability highly sought after by healthcare providers and researchers. The company's focus on innovative biochemical sensors positions it as a key player in the evolving landscape of clinical management and remote patient monitoring, aiming to translate cutting-edge technology into tangible healthcare solutions.
How much funding has Profusa raised?
Profusa has raised a total of $184.7M across 9 funding rounds:
Debt
$1.2M
Private Equity
$2.8M
Series A
$2.8M
Private Equity
$11.3M
Series B
$13.2M
Grant
$7.5M
Series C
$45M
Debt
$1M
Stock/Share Issuance
$100M
Debt (2011): $1.2M, investors not publicly disclosed
Private Equity (2013): $2.8M, investors not publicly disclosed
Series A (2013): $2.8M, investors not publicly disclosed
Private Equity (2015): $11.3M, investors not publicly disclosed
Series B (2015): $13.2M backed by Qihoo 360 and Asset Management Ventures
Grant (2016): $7.5M with participation from Defense Advanced Research Projects Agency
Series C (2018): $45M led by 3E Bioventures Capital, Tasly Pharmaceutical Group, VMS Asset Management, Atinum Investment, and Maxim Integrated Ventures
Debt (2020): $1M supported by PPP
Stock/Share Issuance (2025): $100M featuring Ascent Partners
Key Investors in Profusa
Qihoo 360
Qihoo 360 is a leading Chinese internet company known for its security products and expansive online platform, suggesting a strategic interest in technology integration and user-facing applications.
Asset Management Ventures
Asset Management Ventures, with a long-standing history in venture capital, focuses on partnering with visionary entrepreneurs to build new companies and industries, indicating a preference for disruptive technologies with long-term potential.
3E Bioventures Capital
3E Bioventures Capital is a science-driven venture capital firm that invests in companies addressing unmet medical needs, leveraging expertise, efficiency, and execution to advance drug and product development.
What's next for Profusa?
With the recent major strategic investment, Profusa is poised for accelerated commercialization and further technological development. The company's trajectory, marked by consistent funding rounds including Series B and Series C financing, indicates a strong investor confidence in its unique biosensor technology. The strategic nature of the latest capital injection suggests an emphasis on expanding market reach, scaling production capabilities, and potentially forging key partnerships within the healthcare ecosystem. Future endeavors will likely focus on broader clinical adoption of the Lumee Oxygen Platform and the exploration of new applications for their tissue-integrating biosensor technology, solidifying their position in the advanced medical devices market.
See full Profusa company page
